Ab Development to IND: Early Risk Mitigation, Target Specificity, & mRNA-LNP Delivery скачать в хорошем качестве

Ab Development to IND: Early Risk Mitigation, Target Specificity, & mRNA-LNP Delivery

Traditional pathways for antibody IND submission often overlook opportunities to mitigate risks early or accelerate candidate selection. This 30-minute presentation questions that approach by introducing more strategic, early decision points and examining alternative delivery platforms that could shift the development trajectory, especially in oncology. You’ll learn how to: • De-risk early with target specificity profiling using the proprietary Retrogenix® Cell Microarray, detecting unexpected off-target binding across thousands of human membrane proteins • Leverage translationally relevant models for in vitro and in vivo pharmacology, improving predictive power before IND • Integrate safety screening earlier to reduce late-stage attrition • Explore a complementary delivery strategy using mRNA-LNP technology, unlocking new possibilities for solid tumor immunotherapy and improving scalability Whether optimizing lead candidates or exploring novel delivery modalities, this session offers a fresh perspective on building a more agile and future-proof antibody development program. Click the link below to learn more. https://bit.ly/4oS2P5s